Vaccinex Inc. (VCNX) |
|
1.735 -0.045 (-2.53%)
|
10-01 15:16 |
|
Open: |
1.72 |
Pre. Close: |
1.78 |
|
High:
|
1.76 |
Low:
|
1.71 |
|
Volume:
|
446,777 |
Market Cap:
|
35M |
|
|
|
|
Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company is headquartered in Rochester, New York and currently employs 44 full-time employees. The firm is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The company provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. The company also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.823 - 1.832 |
1.832 - 1.84 |
|
Low:
|
1.729 - 1.739 |
1.739 - 1.748 |
|
Close:
|
1.763 - 1.78 |
1.78 - 1.795 |
|
Technical analysis |
as of: 2020-10-01 2:40:57 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.50 One year: 7.72 |
| Support: |
Support1: 1.63 Support2: 1.36 |
| Resistance: |
Resistance1: 4.71 Resistance2: 6.61 |
| Pivot: |
3.52 |
| Moving Average: |
MA(5): 1.76 MA(20): 3.89
MA(100): 4.62 MA(250): 4.88 |
| MACD: |
MACD(12,26): -1.02 Signal(9): -0.74 |
| Stochastic oscillator: |
%K(14,3): 2.61  %D(3): 2.26 |
| RSI: |
RSI(14): 24.84 |
| 52-week: |
High: 12.23 Low: 1.63 Change(%): -74.0 |
| Average Vol(K): |
3-Month: 112822 10-Days: 256197 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.VCNX has closed above bottom band by 25.2%. Bollinger Bands are 258.2% wider than normal. The large width of the bands suggest high volatility as compared to VCNX's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 29 Sep 2020
A Little Luck Can Go a Long Way with Vaccinex Inc. (VCNX) as it 5-day change was -68.01% - News Daemon
Tue, 29 Sep 2020
Shares in Vaccinex, Inc. (VCNX) -63.92 % down, YTD - Marketing Sentinel
Mon, 28 Sep 2020
Should Vaccinex Inc (VCNX) be in Your Portfolio? - InvestorsObserver
Mon, 28 Sep 2020
We Analyzed the Future Direction of Vaccinex Inc. (VCNX), Here is What We Found - The News Heater
Fri, 25 Sep 2020
Does Vaccinex Inc (VCNX) Have What it Takes to be in Your Portfolio? - InvestorsObserver
Wed, 23 Sep 2020
What is the Market's View on Vaccinex Inc (VCNX) Stock's Price and Volume Trends - InvestorsObserver
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
20 |
| Shares Float (M) |
8 |
|
% Held by Insiders
|
23.39 |
|
% Held by Institutions
|
59.38 |
|
Shares Short (K)
|
52 |
|
Shares Short P. Month (K)
|
41 |
Stock Financials |
|
EPS
|
-1.803 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
-1.740 |
|
Profit Margin
|
|
|
Operating Margin
|
-6850.50 |
|
Return on Assets (ttm)
|
-338.5 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
0.016 |
|
Sales Per Share
|
0.020 |
|
EBITDA (p.s.)
|
-1.363 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-29 |
|
Levered Free Cash Flow (M)
|
-19 |
Stock Valuations |
|
PE Ratio
|
-0.96 |
|
PEG Ratio
|
|
|
Price to Book value
|
-0.99 |
|
Price to Sales
|
86.03 |
|
Price to Cash Flow
|
-1.19 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
